NCIt definition : A combination of two human immunoglobulin G1 (IgG1) monoclonal antibodies C135-LS
and C144-LS directed against the spike protein (SP) of severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), that are isolated from convalescent patients with SARS-CoV-2
infection and engineered with a mutation to prolong their half-lives, that can potentially
be used for immunization against COVID-19. Upon administration, anti-SARS-CoV-2 monoclonal
antibodies C135-LS/C144-LS specifically target and bind to two distinct epitopes on
the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry
into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression
of the disease and accelerate recovery, and may potentially provide temporary protection
against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP
may decrease the potential for virus escape mutants that occur upon treatment with
a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of
efficacy.;